Solid Tumors
BGB-43395 CDK4 inhibitor
- Phase 1: Breast cancer
BG-68501* CDK2 inhibitor
- Phase 1: Breast cancer
BGB-21447 next-gen BCL-2 inhibitor
- Phase 1: Metastatic breastcancer†
Zanidatamab‡ HER2 BsAb
- Phase 3: 1L HER2+ GEA
Tislelizumab-jsgr PD-1 mAb
- Phase 3: Locally advanced ESCC
Xaluritamig§ STEAP1 x CD3 BsAb
- Phase 1: mCRPC
Tislelizumab PD-1 mAb
- Phase 1: Pan-tumor (subcutaneous formulation)
Tarlatamab§ DLL3 x CD3 BsAb
- Phase 3: 2L SCLC, 1L ES-SCLC, LS-SCLC
- Phase 2: 3L SCLC
Tislelizumab PD-1
- Phase 3: 1L UBC
Pamiparib PARP inhibitor
- Phase 3: 2L methotrexate gBRCAm PSOC
BGB-30813 DGKζ inhibitor
- Phase 1: Solid tumors
BGB-A3055 CCR8 mAb
- Phase 1: Solid tumors
BGB-43395 CDK4 inhibitor
- Phase 1: Solid tumors
BG-68501* CDK2 inhibitor
- Phase 1: Solid tumors
BG-C9074|| B7H4-ADC
- Phase 1: Solid tumors
BGB-53038 pan-KRAS inhibitor
- Phase 1: Solid tumors
BG-60366 EGFR CDAC
- Phase 1: Solid tumors
BG-58067 MTA-cooperative PRMT5 inhibitor
- Phase 1: Solid tumors
SHY-2039 MAT2A inhibitor¶
- Phase 1: Solid tumors
BG-C354 B7-H3 ADC
- Phase 1: Solid tumors
BG-C477 CEA ADC
- Phase 1: Solid tumors
BG-C137 FGFR2b ADC
- Phase 1: Solid tumors
BG-T187 EGFR x MET TsAb
- Phase 1: Solid tumors
BGB-R046 IL-15 prodrug
- Phase 1: Solid tumors
BGB-B2033 GPC3 x 4-1BB BsAb
- Phase 1: Solid tumors
BGB-B3227 MUC1 x CD16A BsAb
- Phase 1: Solid tumors
Hematology
Zanubrutinib BTK inhibitor
- Phase 2: B-cell malignancies
- Phase 2: CD79B R/R DLBCL
- Phase 3: TN MCL
- Phase 3: R/R MZL, R/R FL
Sonrotoclax BCL-2 inhibitor
- Phase 2: R/R MCL
- Phase 2: R/R CLL
- Phase 2: R/R WM
- Phase 2: TN CLL/SLL
- Phase 3: TN CLL
- Phase 3: R/R MCL*
BGB-16673 BTK CDAC
- Phase 2: R/R CLL
Blinatumomab§ CD3 x CD19 BsAb
- Phase 2: Pediatric R/R BP-ALL
Sonrotoclax BCL-2 inhibitor
- Phase 1: B-cell malignancies
BGB-16673 BTK CDAC
- Phase 1: B-cell malignancies
BGB-21447 next-gen BCL-2
- Phase 1: B-cell malignancies
Sonrotoclax BCL-2 inhibitor
- Phase 1: AML/MDS
- Phase 1: R/R MM with t(11;14)
- Phase 1: Dose ramp-up*
Tislelizumab-jsgr PD-1 mAb
- Phase 3: R/R cHL
Non-Oncology
Zanubrutinib BTK inhibitor
- Phase 3: Primary membranous nephropathy
BGB-45035 IRAK4 CDAC
- Phase 1: Immunology and inflammation